First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement

Cancer Discovery

Volumn 3, Issue 4, 2013, Pages 406-417

  Tabernero, Josep ^a   Shapiro, Geoffrey I ^d   LoRusso, Patricia M ^g   Cervantes, Andres ^b   Schwartz, Gary K ^h   Weiss, Glen J ⁱ   Paz Ares, Luis ^c   Cho, Daniel C ^e   Infante, Jeffrey R ^j   Alsina, Maria ^a   Gounder, Mrinal M ^h   Falzone, Rick ^f   Harrop, Jamie ^f   White, Amy C Seila ^f   Toudjarska, Iva ^f   Bumcrot, David ^f   Meyers, Rachel E ^f   Hinkle, Gregory ^f   Svrzikapa, Nenad ^f   Hutabarat, Renta M ^f   Clausen, Valerie A ^f   Cehelsky, Jeffrey ^f   Nochur, Saraswathy V ^f   Gamba Vitalo, Christina ^f   Vaishnaw, Akshay K ^f   Sah, Dinah W Y ^f   Gollob, Jared A ^f   Burris III, Howard A ^j   more..

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f ALNYLAM PHARMACEUTICALS   (United States)

^g KARMANOS CANCER INSTITUTE   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ HonorHealth Research Institute   (United States)

^j SARAH CANNON RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALN VSP; ALPHA INTERFERON; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYZINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; KINESIN; PARACETAMOL; RANITIDINE; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD FLOW; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEATH; DISEASE COURSE; DOWN REGULATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERANCE; ENDOMETRIUM CANCER; FATIGUE; FEMALE; FEVER; GENE EXPRESSION; HAPLORHINI; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER FAILURE; LIVER FUNCTION TEST; LIVER METASTASIS; LIVER RESECTION; LIVER TOXICITY; LIVER TUMOR; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SINGLE DRUG DOSE; SPLENECTOMY; TUMOR BIOPSY; TUMOR REGRESSION;

ADULT; AGED; ANIMALS; CELL LINE, TUMOR; CYTOKINES; FEMALE; HUMANS; KINESIN; LIVER NEOPLASMS; MALE; MICE; MICE, SCID; MIDDLE AGED; NANOPARTICLES; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877120847     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0429     Document Type: Article

References (44)

1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specifi c genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-11.
2. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-8.
3. Bumcrot D, Manoharan M, Koteliansky V, Sah DWY. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006; 2: 711-9.
4. Vaishnaw AK, Gollob J, Gamba-Vitalo C, Hutabarat R, Sah D, Meyers R, et al. A status report on RNAi therapeutics. Silence 2010; 8: 1-14.
5. Gollob JA, Bumcrot D, Toudjarska I, Bastian BC, Sah DW, Vaishnaw AK. Progress in the delivery of siRNA therapeutics: potential in uveal melanoma. Drugs Future 2011; 36: 229-39.
6. Rozema DB, Lewis DL, Wakefield DH, Wong SC, Klein JJ, Roesch PL, et al. Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A 2007; 104: 12982-7.
7. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specifi c targeting on the biodistribution and effi cacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A 2007; 104: 15549-54.
8. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specifi c knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005; 65: 8984-92.
9. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010; 464: 1067-70.
10. Koldehoff M, Steckel NK, Beelen DW, Elmaagacli AH. Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin Exp Med 2007; 7: 47-55.
11. Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, Pandey RK, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007; 25: 1149-57.
12. Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 2010; 18: 1357-64.
13. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006; 441: 111-4.
14. Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 2008; 105: 11915-20.
15. Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A, et al. Confi rming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 2009; 119: 661-73.
16. Wahl O, Oswald M, Tretzel L, Herres E, Arend J, Efferth T. Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products. Curr Med Chem 2011; 18: 3136-55.
17. Zhang Y, Xu W. Progress on kinesin spindle protein inhibitors as anticancer agents. Anticancer Agents Med Chem 2008; 8: 698-704.
18. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, et al. Sequence-specifi c potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005; 11: 263-70.
19. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I, et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005; 23: 457-62.
20. Robbins M, Judge A, MacLachlan I. siRNA and innate immunity. Oligonucleotides 2009; 19: 89-102.
21. Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D, et al. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 1992; 52: 6774-81.
22. Senior JH. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 1987; 3: 123-93.
23. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271-84.
24. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010; 7: 653-64.
25. Tang PA, Siu LL, Chen EX, Hotte SJ, Chia S, Schwarz JK, et al. Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs 2008; 26: 257-64.
26. Burris HA, Jones SF, Williams DD, Kathman SJ, Hodge JP, Pandite L, et al. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors. Invest New Drugs 2011; 29: 467-72.
27. Fromont-Racine M, Bertrand E, Pictet R, Grange T. A highly sensitive method for mapping the 5mmtermini of mRNAs. Nucleic Acids Res 1993; 21: 1683-4.
28. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, et al. Therapeutic silencing of an endogenous gene by systemic administration of modifi ed siRNAs. Nature 2004; 432: 173-8.
29. Szebeny J, Muggia F, Gabizo A, Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 2011; 63: 1020-30.
30. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005; 23: 1028-43.
31. Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, Broaddus R, et al. Clinical and biological signifi cance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 2007; 13: 7487-95.
32. Chan JA, Kulke MH. New treatment options for patients with advanced neuroendocrine tumors. Curr Treatment Options Oncol 2011; 12: 136-48.
33. Park MS, Ravi V, Araujo DM. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/ solitary fi brous tumor. C urr Opin Oncol 2010; 22: 351-5.
34. O'Connor JPB, Jackson A, Parker GJM, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007; 96: 189-95.
35. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantifi cation of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33; e179.
36. Mochida S, Ishikawa K, Inao M, Shibuya M, Fujiwara K. Increased expression of vascular endothelial growth factor and its receptors, fl t-1 and KDR/fl k-1, in regenerating rat liver. Biochem Biophys Res Comm 1996; 226: 176-9.
37. Shimizu H, Miyazaki M, Wakabayashi Y, Mitsuhashi N, Kato A, Ito H, et al. Vascular endothelial growth factor secreted by replicating hepatocytes induces sinusoidal endothelial cell proliferation during regeneration after partial hepatectomy in rats. J Hepatol 2001; 34: 683-9.
38. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell cancer. N Engl J Med 2007; 356: 125-34.
39. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-13.
40. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6: 465-77.
41. Thukral A, Thomasson DM, Chow CK, Eulate R, Wedam SB, Gupta SN, et al. Infl ammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab-initial experience. Radiology 2007; 244: 727-35.
42. Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamics measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005; 23: 5464-73.
43. Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2011; 29: 2259-65.
44. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.